The US FDA will make its draft requirements for demonstrating the interchangeability of biosimilars and their reference biologic less burdensome to help stimulate development of follow-on products, Commissioner Scott Gottlieb said at an April 19 policy conference sponsored by the Pharmaceutical Care Management Association.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?